{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Infectious+Uveitis&page=2",
    "query": {
      "condition": "Non-Infectious Uveitis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Infectious+Uveitis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T14:53:24.362Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02258854",
      "title": "An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitis"
      ],
      "interventions": [
        {
          "name": "Dose 2 gevokizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XOMA (US) LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2014-03",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2015-10-16",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 33,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 30 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258854"
    },
    {
      "nct_id": "NCT05523765",
      "title": "A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-infectious Intermediate Uveitis",
        "Non-infectious Posterior Uveitis",
        "Non-infectious Pan Uveitis"
      ],
      "interventions": [
        {
          "name": "Brepocitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Priovant Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 26,
      "start_date": "2022-11-14",
      "completion_date": "2024-07-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05523765"
    },
    {
      "nct_id": "NCT03131154",
      "title": "SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-infectious Anterior Uveitis"
      ],
      "interventions": [
        {
          "name": "ADX-102 Ophthalmic Solution (0.5%)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of ADX-102 Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aldeyra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 123,
      "start_date": "2017-04-26",
      "completion_date": "2019-04-26",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03131154"
    },
    {
      "nct_id": "NCT06085079",
      "title": "Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Uveitis, Posterior",
        "Uveitis, Anterior",
        "Uveitis, Intermediate",
        "Panuveitis"
      ],
      "interventions": [
        {
          "name": "Ixekizumab Prefilled Syringe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye Research and Surgery Institution",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-06-01",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2023-10-16",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 1,
      "location_summary": "Waltham, Massachusetts",
      "locations": [
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06085079"
    },
    {
      "nct_id": "NCT00404742",
      "title": "A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitis, Posterior",
        "Uveitis, Intermediate",
        "Panuveitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LX211",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lux Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 232,
      "start_date": "2007-01",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2012-06-22",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00404742"
    },
    {
      "nct_id": "NCT05070728",
      "title": "Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitis",
        "Uveitis, Posterior",
        "Uveitis, Intermediate"
      ],
      "interventions": [
        {
          "name": "Sham Injector",
          "type": "DRUG"
        },
        {
          "name": "FAI Insert",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-10-13",
      "completion_date": "2023-04-12",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 1,
      "location_summary": "Waltham, Massachusetts",
      "locations": [
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05070728"
    },
    {
      "nct_id": "NCT04018599",
      "title": "Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Polyarticular Juvenile Idiopathic Arthritis",
        "Psoriatic Arthritis",
        "Ankylosing Spondylitis",
        "Crohn Disease",
        "Ulcerative Colitis",
        "Plaque Psoriasis",
        "Pediatric Plaque Psoriasis",
        "Pediatric Crohns Disease",
        "Hidradenitis Suppurativa",
        "Non-infectious Uveitis"
      ],
      "interventions": [
        {
          "name": "40 mg MSB11022",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fresenius Kabi SwissBioSim GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 216,
      "start_date": "2019-07-15",
      "completion_date": "2020-03-17",
      "has_results": false,
      "last_update_posted_date": "2020-03-25",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04018599"
    },
    {
      "nct_id": "NCT01717170",
      "title": "Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Intermediate Uveitis",
        "Posterior Uveitis",
        "Pan-uveitis"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-03",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2017-04-28",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01717170"
    },
    {
      "nct_id": "NCT00326508",
      "title": "Combination Daclizumab/Denileukin Diftitox to Treat Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-infectious Intermediate and Posterior Uveitis"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2006-05-11",
      "completion_date": "2006-12-20",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326508"
    },
    {
      "nct_id": "NCT00404885",
      "title": "A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitis, Anterior",
        "Panuveitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LX211",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lux Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2007-01",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2012-06-22",
      "last_synced_at": "2026-07-22T14:53:24.362Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00404885"
    }
  ]
}